These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 30235247)

  • 41. Is fluoroquinolone monotherapy a useful alternative treatment for Pseudomonas aeruginosa bacteraemia?
    Wu PF; Lin YT; Wang FD; Yang TC; Fung CP
    Infection; 2018 Jun; 46(3):365-373. PubMed ID: 29556979
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Beta-lactam and fluoroquinolone combination antibiotic therapy for bacteremia caused by gram-negative bacilli.
    Al-Hasan MN; Wilson JW; Lahr BD; Thomsen KM; Eckel-Passow JE; Vetter EA; Tleyjeh IM; Baddour LM
    Antimicrob Agents Chemother; 2009 Apr; 53(4):1386-94. PubMed ID: 19164144
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Monotherapy or combination therapy? The Pseudomonas aeruginosa conundrum.
    Traugott KA; Echevarria K; Maxwell P; Green K; Lewis JS
    Pharmacotherapy; 2011 Jun; 31(6):598-608. PubMed ID: 21923444
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia.
    Morata L; Cobos-Trigueros N; Martínez JA; Soriano A; Almela M; Marco F; Sterzik H; Núñez R; Hernández C; Mensa J
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4833-7. PubMed ID: 22751533
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A retrospective analysis of
    Shi Q; Huang C; Xiao T; Wu Z; Xiao Y
    Antimicrob Resist Infect Control; 2019; 8():68. PubMed ID: 31057792
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Outcomes of empiric aminoglycoside monotherapy for Pseudomonas aeruginosa bacteremia.
    Phe K; Bowers DR; Babic JT; Tam VH
    Diagn Microbiol Infect Dis; 2019 Apr; 93(4):346-348. PubMed ID: 30522794
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rates, predictors and mortality of community-onset bloodstream infections due to Pseudomonas aeruginosa: systematic review and meta-analysis.
    Rojas A; Palacios-Baena ZR; López-Cortés LE; Rodríguez-Baño J
    Clin Microbiol Infect; 2019 Aug; 25(8):964-970. PubMed ID: 30995530
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Effect of adequate initial antimicrobial therapy on mortality in critical patients with Pseudomonas aeruginosa bacteremia].
    González AL; Leal AL; Cortés JA; Sánchez R; Barrero LI; Castillo JS; Álvarez CA
    Biomedica; 2014 Apr; 34 Suppl 1():58-66. PubMed ID: 24968037
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk Factors and Outcomes of Antibiotic-resistant Pseudomonas aeruginosa Bloodstream Infection in Adult Patients With Acute Leukemia.
    Zhao Y; Lin Q; Liu L; Ma R; Chen J; Shen Y; Zhu G; Jiang E; Mi Y; Han M; Wang J; Feng S
    Clin Infect Dis; 2020 Dec; 71(Suppl 4):S386-S393. PubMed ID: 33367574
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pseudomonas aeruginosa bacteremia after burn injury: the impact of multiple-drug resistance.
    Theodorou P; Thamm OC; Perbix W; Phan VT
    J Burn Care Res; 2013; 34(6):649-58. PubMed ID: 23817000
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tree-structured survival analysis of patients with Pseudomonas aeruginosa bacteremia: A multicenter observational cohort study.
    Yoon YK; Kim HA; Ryu SY; Lee EJ; Lee MS; Kim J; Park SY; Yang KS; Kim SW;
    Diagn Microbiol Infect Dis; 2017 Feb; 87(2):180-187. PubMed ID: 27863948
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies.
    Trecarichi EM; Tumbarello M; Caira M; Candoni A; Cattaneo C; Pastore D; Fanci R; Nosari A; Vianelli N; Busca A; Spadea A; Pagano L
    Haematologica; 2011 Jan; 96(1):e1-3; author reply e4. PubMed ID: 21193424
    [No Abstract]   [Full Text] [Related]  

  • 53. Risk factors for mortality in patients with bloodstream infections caused by carbapenem-resistant Pseudomonas aeruginosa: clinical impact of bacterial virulence and strains on outcome.
    Jeong SJ; Yoon SS; Bae IK; Jeong SH; Kim JM; Lee K
    Diagn Microbiol Infect Dis; 2014 Oct; 80(2):130-5. PubMed ID: 25112900
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Outcomes of hospitalized neutropenic oncology patients with Pseudomonas aeruginosa bloodstream infections: focus on oral fluoroquinolone conversion.
    Yan LZ; Herrington JD
    J Oncol Pharm Pract; 2016 Aug; 22(4):584-90. PubMed ID: 26156260
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: Facing the perfect storm.
    Recio R; Villa J; Viedma E; Orellana MÁ; Lora-Tamayo J; Chaves F
    Int J Antimicrob Agents; 2018 Aug; 52(2):172-179. PubMed ID: 29621591
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection.
    Lodise TP; Patel N; Kwa A; Graves J; Furuno JP; Graffunder E; Lomaestro B; McGregor JC
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3510-5. PubMed ID: 17646415
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis.
    Zelenitsky SA; Harding GK; Sun S; Ubhi K; Ariano RE
    J Antimicrob Chemother; 2003 Oct; 52(4):668-74. PubMed ID: 12951354
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of combination therapy and early de-escalation on outcome of ventilator-associated pneumonia caused by Pseudomonas aeruginosa.
    Deconinck L; Meybeck A; Patoz P; Van Grunderbeeck N; Boussekey N; Chiche A; Delannoy PY; Georges H; Leroy O
    Infect Dis (Lond); 2017 May; 49(5):396-404. PubMed ID: 28092204
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bacterial and clinical characteristics of health care- and community-acquired bloodstream infections due to Pseudomonas aeruginosa.
    Hattemer A; Hauser A; Diaz M; Scheetz M; Shah N; Allen JP; Porhomayon J; El-Solh AA
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3969-75. PubMed ID: 23733476
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antibiotic treatment adequacy and death among patients with Pseudomonas aeruginosa airway infection.
    Eklöf J; Gliese KM; Ingebrigtsen TS; Bodtger U; Jensen JS
    PLoS One; 2019; 14(12):e0226935. PubMed ID: 31891624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.